GuoLine Advisory Pte Ltd Has $36.93 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

GuoLine Advisory Pte Ltd lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 61.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,600 shares of the company’s stock after purchasing an additional 110,000 shares during the period. Novo Nordisk A/S makes up about 4.5% of GuoLine Advisory Pte Ltd’s holdings, making the stock its 11th biggest position. GuoLine Advisory Pte Ltd’s holdings in Novo Nordisk A/S were worth $36,928,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Westside Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after buying an additional 649 shares in the last quarter. Lazard Asset Management LLC grew its stake in Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after purchasing an additional 964,640 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Novo Nordisk A/S by 38.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after purchasing an additional 26,067 shares in the last quarter. Advisor Resource Council purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $997,000. Finally, Procyon Advisors LLC grew its stake in Novo Nordisk A/S by 47.7% in the fourth quarter. Procyon Advisors LLC now owns 55,026 shares of the company’s stock valued at $5,692,000 after purchasing an additional 17,783 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $1.00 during trading hours on Friday, hitting $143.49. 1,670,353 shares of the company’s stock were exchanged, compared to its average volume of 4,439,158. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a market capitalization of $643.92 billion, a price-to-earnings ratio of 49.91, a PEG ratio of 1.43 and a beta of 0.41. The company’s 50-day moving average price is $134.16 and its 200-day moving average price is $122.88.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVO. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.